{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:32:02Z","timestamp":1768444322114,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ctrv.2022.102373","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T13:14:24Z","timestamp":1646745264000},"page":"102373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Immunotherapy in advanced anal cancer: Is the beginning of a new era?"],"prefix":"10.1016","volume":"105","author":[{"given":"Davide","family":"Ciardiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Pio","family":"Guerrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Parente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana Pia","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ctrv.2022.102373_b0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2022.102373_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ctrv.2018.02.001","article-title":"Anal squamous cell carcinoma - State of the art management and future perspectives","volume":"65","author":"Martin","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ctrv.2022.102373_b0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amsu.2020.04.016","article-title":"Squamous cell anal cancer: Management and therapeutic options","volume":"55","author":"Pessia","year":"2020","journal-title":"Ann Med Surg (Lond)"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102373_b0020","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3390\/cancers13092180","article-title":"Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer","volume":"13","author":"Carr","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102373_b0025","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-00946-3","article-title":"Immunotherapy in Anal Cancer","volume":"22","author":"Phuong","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2022.102373_b0030","article-title":"How I treat anal squamous cell carcinoma","volume":"4","author":"Martini","year":"2020","journal-title":"ESMO Open."},{"issue":"15","key":"10.1016\/j.ctrv.2022.102373_b0035","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.3390\/cancers13153895","article-title":"Present and Future Research on Anal Squamous Cell Carcinoma","volume":"13","author":"Spehner","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102373_b0040","doi-asserted-by":"crossref","first-page":"101084","DOI":"10.1016\/j.tranon.2021.101084","article-title":"A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma","volume":"14","author":"Iseas","year":"2021","journal-title":"Transl Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102373_b0045","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3390\/cancers11121846","article-title":"Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas","volume":"11","author":"Morel","year":"2019","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102373_b0050","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2013.52.3464","article-title":"Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal","volume":"32","author":"Serup-Hansen","year":"2014","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102373_b0055","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mdt396","article-title":"DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3566-0","article-title":"Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102373_b0065","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicenter, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2022.102373_b0070","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975356","article-title":"Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2022.102373_b0075","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2022.102373_b0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2021.11.019","article-title":"Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies","volume":"162","author":"Stouvenot","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102373_b0085","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102373_b0090","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2022.102373_b0095","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/JEP.S262342","article-title":"Emerging and Experimental Agents for Anal Cancer: What is New?","volume":"13","author":"Farias","year":"2021","journal-title":"J Exp Pharmacol."},{"issue":"11","key":"10.1016\/j.ctrv.2022.102373_b0100","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1541-7786.MCR-17-0060","article-title":"Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal","volume":"15","author":"Morris","year":"2017","journal-title":"Mol Cancer Res."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102373_b0105","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/cancers12092516","article-title":"Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma","volume":"12","author":"Wessely","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102373_b0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40778-020-00170-6","article-title":"Virus-specific T cells for malignancies - then, now and where to?","volume":"6","author":"Sharma","year":"2020","journal-title":"Curr Stem Cell Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102373_b0115","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/jitc-2020-001395","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","volume":"8","author":"Strauss","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102373_b0120","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.20","article-title":"HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53","volume":"112","author":"Meulendijks","year":"2015","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102373_b0125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/bjc.2016.398","article-title":"Biomarkers in anal cancer: from biological understanding to stratified treatment","volume":"116","author":"Jones","year":"2017","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102373_b0130","doi-asserted-by":"crossref","first-page":"e1288331","DOI":"10.1080\/2162402X.2017.1288331","article-title":"Human papilloma virus load and PD-1\/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy","volume":"6","author":"Balermpas","year":"2017","journal-title":"Oncoimmunology"},{"issue":"18","key":"10.1016\/j.ctrv.2022.102373_b0135","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.3390\/ijms21186838","volume":"21","author":"Spehner","year":"2020","journal-title":"IJMS"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102373_b0140","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaoncol.2017.0115","article-title":"Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy","volume":"3","author":"Yanik","year":"2017","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.ctrv.2022.102373_b0145","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdw152","article-title":"Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes","volume":"27","author":"Chung","year":"2016","journal-title":"Ann Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102373_b0150","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-16-2017","article-title":"Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma","volume":"23","author":"Mouw","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1309\/X4UADHVN317V2XMW","article-title":"Epidermal growth factor receptor expression in anal canal carcinoma","volume":"124","author":"L\u00ea","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102373_b0160","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/CAD.0000000000000383","article-title":"Epidermal growth factor receptor inhibition in metastatic anal cancer","volume":"27","author":"Rogers","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2022.102373_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 Distribution and Perspective for Cancer Immunotherapy\u2014Blockade, Knockdown, or Inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102373_b0170","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41416-020-0834-6","article-title":"Emerging role of PTEN loss in evasion of the immune response to tumours","volume":"122","author":"Vidotto","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2022.102373_b0175","doi-asserted-by":"crossref","first-page":"v770","DOI":"10.1093\/annonc\/mdz268.030","article-title":"Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma","volume":"30","author":"Borg","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102373_b0180","doi-asserted-by":"crossref","first-page":"903","DOI":"10.6004\/jnccn.2018.7040","article-title":"Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal","volume":"16","author":"Morris","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2022.102373_b0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/tgh.2019.08.02","article-title":"Anal cancer and immunotherapy\u2014are we there yet?","volume":"4","author":"Bian","year":"2019","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2022.102373_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2022.102373_b0195","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2020.38.15_suppl.4020","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102373_b0200","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2272","article-title":"LBA42 POD1UM-202: phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy","volume":"31","author":"Rao","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102373_b0205","doi-asserted-by":"crossref","first-page":"102172","DOI":"10.1016\/j.ctrv.2021.102172","article-title":"Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer","volume":"97","author":"Bourhis","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102373_b0210","doi-asserted-by":"crossref","first-page":"e000753","DOI":"10.1136\/esmoopen-2020-000753","article-title":"Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer","volume":"5","author":"Fasano","year":"2020","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102373_b0215","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2022.102373_b0220","article-title":"Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival","author":"Ciardiello","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102373_b0225","doi-asserted-by":"crossref","first-page":"e002996","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study","volume":"9","author":"Lonardi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102373_b0235","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.18632\/oncotarget.27536","article-title":"A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent\/recurrent loco-regional or metastatic anal cancer","volume":"11","author":"Eng","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2022.102373_b0240","doi-asserted-by":"crossref","first-page":"102288","DOI":"10.1016\/j.ctrv.2021.102288","article-title":"Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives","volume":"100","author":"Mandriani","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102373_b0245","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.ctrv.2022.102373_b0250","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human","volume":"37","author":"Doran","year":"2019","journal-title":"Phase I\/II Study. J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102373_b0255","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02696-6","article-title":"Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF\u03b2 enhance the efficacy of cancer immunotherapy","volume":"9","author":"Ravi","year":"2018","journal-title":"Nat Commun"},{"issue":"424","key":"10.1016\/j.ctrv.2022.102373_b0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102373_b0270","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","article-title":"Clinical development of therapies targeting TGF\u03b2: current knowledge and future perspectives","volume":"31","author":"Ciardiello","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102373_b0275","doi-asserted-by":"crossref","unstructured":"O \u2013 Strauss J, Gatti-Mays M, Cho BC, et al. Long-term follow-up of patients with human papillomavirus (HPV)\u2013associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1. ESMO Congress 2021(16-21 September).","DOI":"10.1016\/j.annonc.2021.08.1342"},{"issue":"suppl_4","key":"10.1016\/j.ctrv.2022.102373_b0280","first-page":"S409","article-title":"Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer","volume":"31","author":"Morris","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102373_b0285","first-page":"8","article-title":"407 Preliminary safety, pharmacokinetics\/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors","author":"Shum","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ctrv.2022.102373_b0290","first-page":"43","article-title":"RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial","volume":"23","author":"Martin","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102373_b0295","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102373_b0300","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0305","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102373_b0310","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","article-title":"Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?","volume":"26","author":"Apetoh","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102373_b0315","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0320","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0196-72","article-title":"Loss of normal p53 function confers sensitization to Taxol by increasing G2\/M arrest and apoptosis","volume":"2","author":"Wahl","year":"1996","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0325","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-06841-1","article-title":"Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial","volume":"20","author":"Kim","year":"2020","journal-title":"BMC Cancer"},{"issue":"S3","key":"10.1016\/j.ctrv.2022.102373_b0330","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.21037\/jtd.2018.01.130","article-title":"Combining radiation plus immunotherapy to improve systemic immune response","volume":"10","author":"Cushman","year":"2018","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0335","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0156-7","article-title":"Current clinical trials testing the combination of immunotherapy with radiotherapy","volume":"4","author":"Kang","year":"2016","journal-title":"J Immunotherapy Cancer"},{"key":"10.1016\/j.ctrv.2022.102373_b0340","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.799957","article-title":"The Research Progress of PD-1\/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy","volume":"11","author":"Wen","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102373_b0345","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102373_b0350","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:26:24Z","timestamp":1759656384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":70,"alternative-id":["S0305737222000378"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102373","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in advanced anal cancer: Is the beginning of a new era?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102373"}}